Product nameAnti-VEGFA antibody [EPR20705]
See all VEGFA primary antibodies
DescriptionRabbit monoclonal [EPR20705] to VEGFA
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human VEGFA aa 50-150. The exact sequence is proprietary.
Database link: P15692
- WB: Human fetal vessel lysate; HeLa, HUVEC, SH-SY5Y, Neuro-2a, bEND.3, C6 and RAW 264.7 whole cell lysates.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab214424 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 40 kDa (predicted molecular weight: 27 kDa).|
FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
- Information by UniProt
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
All lanes : Anti-VEGFA antibody [EPR20705] (ab214424) at 1/1000 dilution
Lane 1 : Human fetal vessel lysate
Lane 2 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Lane 3 : HUVEC (human umbilical vein endothelial cell line) whole cell lysate
Lane 4 : SH-SY5Y (human neuroblastoma cell line from bone marrow) whole cell lysate
Lane 5 : Neuro-2a (mouse neuroblastoma cell line) whole cell lysate
Lane 6 : bEND.3 (mouse brain endothelioma cell line) whole cell lysate
Lane 7 : C6 (rat glial tumor cell line) whole cell lysate
Lane 8 : RAW 264.7 (mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 27 kDa
Observed band size: 40 kDa why is the actual band size different from the predicted?
Blocking/Dilution: 5% NFDM/TBST
Exposure time : Lanes 1-4/7-8: 3 minutes; Lane 5: 41 seconds; Lane 6: 15 seconds.
The blot was developed on a BIO-RAD® ChemiDoc™ MP instrument.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab214424 has not yet been referenced specifically in any publications.